Document Type : Original Article
Authors
1 Department of Anatomical Sciences, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
2 Student Research Committee, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
3 Nephrology and Kidney Transplant Research Center, Urmia University of Medical Sciences, Urmia, Iran
4 Department of Physiology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
Abstract
Obesity causes many problems such as cardiovascular and chronic kidney diseases. The aim of this study was to evaluate the efficacy of retinoic acid and atorvastatin co-administration in kidneys protection against high-fat diet induced damage. Twenty-five male Wistar rats (200.00 ± 20.00 g) were divided into five groups: 1) Control (standard diet), 2) High-fat diet (cholesterol 1.00%, 75 days), 3) High-fat diet + atorvastatin (20.00 mg kg-1 per day, orally, on the 30th day, for 45 consecutive days), 4) High-fat diet + retinoic acid (5 mg kg-1per day, orally, on the 30th day, for 45 consecutive days), and 5) High fat diet + atorvastatin and retinoic acid. At the end, blood and tissue samples were collected for biochemical and histological analyses. The results showed that atorvastatin and retinoic acid alone and in combination decreased cholesterol and low-density lipoprotein and increased high-density lipoprotein in high-fat diet. Also, atorvastatin – caused total antioxidant capacity increase and protein carbonyl content decrease the in the renal tissue. Atorvastatin also prevented high-fat diet-induced renal histological injury. Treatment with atorvastatin significantly mitigates high-fat diet-induced renal changes probably due to its potent antioxidant and lipid-lowering effects. The effect of retinoic acid in renal protection in a high-fat diet is far less than that of atorvastatin. The protective effect of the combination of these two agents in the high-fat diet on the kidneys seems to be due to the effect of atorvastatin.
Keywords
Main Subjects
- Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005;352(11):1138-1145.
- Kramer H, Luke A. Obesity and kidney disease: A big dilemma. Curr Opin Nephrol Hypertens 2007; 16(3):237-241.
- Odermatt A. The Western-style diet: A major risk factor for impaired kidney function and chronic kidney disease. Am J Physiol Renal Physiol 2011; 301(5):F919- F931.
- Liu Y, Wang Z, Yin W, et al. Severe insulin resistance and moderate glomerulosclerosis in a minipig model induced by high-fat/ high-sucrose/ high-cholesterol diet. Exp Anim 2007;56(1):11-20.
- Papafragkaki DK, Tolis G. Obesity and renal disease: A possible role of leptin. Hormones (Athens) 2005;4(2):90-95.
- Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004;140(3):167-174.
- Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16(7):2134-2140.
- Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003;16(11Pt 1):952-958.
- Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41(3):565-570.
- Gheith OA, Sobh MA, Mohamed Kel S, et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 2002;91(4):612-619.
- Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336(7645):645-651.
- Koren MJ, Davidson MH, Wilson DJ, et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis 2009;53(5):741-750.
- Nakamura H, Mizuno K, Ohashi Y, et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009;206(2):512-517.
- Stancu C, Sima A. Statins: Mechanism of action and effects. J Cell Mol Med 2001;5(4):378-387.
- Evans TR, Kaye SB. Retinoids: Present role and future potential. Br J Cancer 1999;80(1-2):1-8.
- Zobali F, Avci A, Canbolat O, et al. Effects of vitamin A and insulin on the antioxidative state of diabetic rat heart: A comparison study with combination treatment. Cell Biochem Funct 2002;20(2):75-80.
- Xu Q, Lucio-Cazana J, Kitamura M, et al. Retinoids in nephrology: Promises and pitfalls. Kidney Int 2004;66(6):2119-2131.
- Lehrke I, Schaier M, Schade K, et al. Retinoid receptor-specific agonists alleviate experimental glomerulo-nephritis. Am J Physiol Renal Physiol 2002; 282(4):F741-F751.
- Wagner J, Dechow C, Morath C, et al. Retinoic acid reduces glomerular injury in a rat model of glomerular damage. J Am Soc Nephrol 2000;11(8):1479-1487.
- Zhong Y, Wu Y, Liu R, et al. Novel retinoic acid receptor alpha agonists for treatment of kidney disease. PLoS One 2011;6(11):e27945.
- Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors. Blood 2009; 113(4):775-783.
- Zhang L, Zhang ZG, Ding GL, et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 2005;112(22):3486-3494.
- Levine R, Garland D, Oliver CN, et al. Determination of carbonyl content of oxidatively modified proteins. Methods Enzymal 1990;186:464-478.
- Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: The FRAP assay. Anal Biochem 1996;239(1):70-76.
- Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193(1):265-275.
- Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001;12(6):1211-1217.
- Maddox DA, Alavi FK, Santella RN, et al. Prevention of obesity-linked renal disease: Age-dependent effects of dietary food restriction. Kidney Int 2002;62(1):208-219.
- Fassett RG, Robertson IK, Ball MJ, et al. Effect of atorvastatin on kidney function in chronic kidney disease: A randomised double-blind placebo-controlled trial. Atherosclerosis 2010;213(1):218-224.
- Malhotra HS, Goa KL. Atorvastatin - An updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001;61(12):1835-1881.
- Chalasani N. Statins and hepatotoxicity: Focus on patients with fatty liver. Hepatology 2005; 41(4):690-695.
- Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84(4):1381-1478.
- Chade AR, Lerman A, Lerman LO. Kidney in early atherosclerosis. Hypertension 2005;45(6):1042-1049.
- Ciftci GA, Ertorun I, Akalin A, et al. The effects of atorvastatin on antioxidant/anti-inflammatory properties of HDLs in hypercholesterolemics. Turk JMed Sci 2015;45(2):345-351.
- Nishimura C, Kuriyama K. Alteration of lipid peroxide and endogenous antioxidant contents in retina of streptozotocin-induced diabetic rats: Effect of vitamin A administration. Jpn J Pharmacol 1985;37(4):365-372.
- Noeman SA, Hamooda HE, Baalash AA. Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats. Diabetol Metab Syndr 2011;3(1):17.
- Stoll LL, McCormick ML, Denning GM, et al. Antioxidant effects of statins. Drugs Today (Barc) 2004;40 (12):975-990.
- Rutkowski P, Klassen A, Sebekova K, et al. Renal disease in obesity: The need for greater attention. J Ren Nutr 2006;16(3):216-223.
- O’Donnell MP, Kasiske BL, Cleary MP, et al. Effects of genetic obesity on renal status and function in the Zucker rat. J Lab Clin Med 1985;106(5):605-610.
)